Telix Pharmaceuticals TLX
Valuation
Multiples measured against the stock's own five-year history
Below its usual level · 40th percentile, 5-year average 40.9x
#2803 of 2993 stocks by PE (1 = cheapest)
Below its usual level · 36th percentile, 5-year average 9.4x
#4771 of 5330 stocks by PB (1 = cheapest)
Below its usual level · 23rd percentile, 5-year average 5.9x
#3454 of 5155 stocks by PS (1 = cheapest)
P/E over five years
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Morningstar fair value estimate
| Multiple | Current | Forward | 5y average | Percentile vs. own history | Industry rank |
|---|---|---|---|---|---|
| PB | 7.53 | – | 9.37 | 36% (cheaper than usual) | #4771 of 5330 (1 = cheapest) |
| PE | 95.15 | 312.55 | 40.89 | 40% (cheaper than usual) | #2803 of 2993 (1 = cheapest) |
| PS | 3.51 | 3.09 | 5.89 | 23% (cheaper than usual) | #3454 of 5155 (1 = cheapest) |
Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.
No comments yet — be the first to weigh in on TLX.
Sign in to join the discussion.